StockNews.com downgraded shares of Cytokinetics (NASDAQ:CYTK – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning. A number of other research firms have also weighed in on CYTK. Cantor Fitzgerald lowered their price objective on shares of Cytokinetics from $61.00 to $59.00 and set […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) Director John T. Henderson sold 4,166 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $37.77, for a total transaction of $157,349.82. Following the sale, the director now directly owns 25,420 shares of the company’s stock, […]
StockNews.com upgraded shares of Cytokinetics (NASDAQ:CYTK – Get Rating) from a sell rating to a hold rating in a research note released on Tuesday morning. A number of other analysts have also weighed in on the stock. UBS Group upped their target price on shares of Cytokinetics from $61.00 to $62.00 in a research note […]
Cytokinetics (NASDAQ:CYTK – Get Rating) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday. A number of other research firms also recently issued reports on CYTK. Mizuho initiated coverage on shares of Cytokinetics in a research report on Monday, March 6th. […]
Cytokinetics (NASDAQ:CYTK – Get Rating) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.14), Briefing.com reports. Cytokinetics had a negative return on equity of 1,401.63% and a negative net margin of 439.05%. The company had revenue of $4.60 […]